Dr. Reddy's Laboratories DRREDDY
US generics major (largest single market), India branded formulations, emerging markets, APIs (PSAI) and biosimilars
Mapped in 2 themes: Nifty 50 and Pharmaceuticals.
Where Dr. Reddy's Laboratories sits in the supply chain
Dr. Reddy's Laboratories appears in 2 supply-chain layers in one theme, Pharmaceuticals.
Pharmaceuticals › Generics (US & export)
Direct supplierOther companies in this layer
Pharmaceuticals › Biosimilars, vaccines & biologics
Emerging entrantOther companies in this layer
Index membership
Dr. Reddy's Laboratories is in the Nifty 50 (NSE industry: Healthcare).
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 28,011 | 32,644 | 33,700 |
| Net profit | 5,578 | 5,725 | 4,158 |
Latest-year revenue ₹33,700 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- Net-cash balance sheet and diversified geographies (US, India, Russia/CIS, Europe)
- Among the first with generic semaglutide in India (Obeda, Mar 2026), with other semaglutide markets to follow
- Consumer health platform (Nicotinell bought from Haleon) and biosimilars pipeline
Risks
- gRevlimid's end cut US sales and Q1 FY27 profit sharply; a semaglutide API provision (~₹240 Cr per reports) added to the hit
- US generic tariff clock from Aug 2028
- Higher solvent and freight costs (Middle East conflict) pressured margins
Common questions
What does Dr. Reddy's Laboratories do?
US generics major (largest single market), India branded formulations, emerging markets, APIs (PSAI) and biosimilars.
Where does Dr. Reddy's Laboratories sit in the supply chain?
Dr. Reddy's Laboratories (NSE: DRREDDY) is mapped in 2 supply-chain layers: Generics (US & export) (Pharmaceuticals); and Biosimilars, vaccines & biologics (Pharmaceuticals).
Who are Dr. Reddy's Laboratories' peers?
In the Generics (US & export) layer of Pharmaceuticals: Aurobindo Pharma, Lupin, Zydus Lifesciences, Cipla, Sun Pharmaceutical Industries, Alembic Pharmaceuticals and 6 more.
What is Dr. Reddy's Laboratories' market cap and valuation?
As of 30 Oct 2026: market cap ₹1.13L Cr, P/E 40.5x, ROCE 13.0%, ROE 11.2%, dividend yield 0.59%.